VIDEX
LOE ApproachingNDAORALFOR SOLUTIONPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIDEX is an oral small-molecule antiretroviral approved in 1991 for HIV treatment. The drug is a nucleoside reverse transcriptase inhibitor (NRTI) that works by blocking HIV replication. It represents a foundational class in antiretroviral therapy with a well-established safety and efficacy profile.
LOE Approaching
Product is in advanced lifecycle maturity with moderate competitive pressure (30/100), signaling reduced team expansion and focus on value defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Treatment IND (Investigational New Drug) Protocol for the Use of Videx (2',3'-Dideoxyinosine, ddI) in Patients With Acquired Immunodeficiency Syndrome (AIDS) or AIDS- Related Complex (ARC) Who Are Intolerant to Zidovudine (Retrovir)
HIV Infections
Comparing Side Effects of Two Forms of Videx in HIV-Infected Adults
200 enrolled
HIV Infections
Career Relevance
Working on VIDEX offers limited career growth given its LOE-approaching status and zero linked job count. Roles focus on market maintenance, managed care negotiation, and compliance rather than launch excitement or pipeline development.
Brand Manager
Worked on VIDEX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.